樂觀
$26.69
情境價格
$38.610
+1.355 (+3.51%)收盤時
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
BioLife Solutions Inc is currently not a strong buy due to recent downgrades and insider selling, despite a significant year-to-date increase of 56.13%.
Benchmark
—
2026-08-10
Benchmark
2026-08-10
目標價
—
Jefferies
$31
2026-07-23
Jefferies
2026-07-23
目標價
$31
H.C. Wainwright
$31
2026-07-23
H.C. Wainwright
2026-07-23
目標價
$31
TD Cowen
$31
2026-07-22
TD Cowen
2026-07-22
目標價
$31
Craig-Hallum
$31
2026-07-22
Craig-Hallum
2026-07-22
目標價
$31
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Freshworks Joins S&P SmallCap 600 Index

Biotech Stocks Reach 52-Week Highs Driven by Key Catalysts

Investor Rights Law Firm Investigates Multiple Companies for Potential Violations

Biotech Stocks Reach 52-Week Highs Driven by Key Catalysts

Investor Rights Law Firm Investigates Multiple Companies
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).
BioLife Solutions Inc is currently not a strong buy due to recent downgrades and insider selling, despite a significant year-to-date increase of 56.13%.
3 analysts cover BLFS: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 33.25.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。